Literature DB >> 6231334

Plasma levels and clinical response during treatment with clomipramine.

C Faravelli, A Ballerini, A Ambonetti, A D Broadhurst, M Das.   

Abstract

The plasma levels of clomipramine (CI) and its major metabolite desmethylclomipramine (DMCI) may be related to clinical response during treatment of depression. Not all workers have been able to demonstrate such a relationship. The many factors which may affect clinical response include sample selection, assessment and its quantification and kinetic factors. A further investigation into the relationship between plasma levels and response was, therefore, carried out taking these into account and attempting to control them. Sixty-two patients with depressive illness were included. The plasma levels of CI + DMCI as measured on the 28th day of treatment were correlated against clinical response at the time. Patients with the highest combined plasma levels showed the best response. Patients with intermediate plasma levels showed more modest response, whilst lowest plasma levels tended to be shown by patients who exhibited an inadequate response or who relapsed during subsequent outpatient follow-up. The threshold value for satisfactory antidepressant effect appeared to be a combined CI + DMCI plasma level of 160-200 mg/ml.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231334     DOI: 10.1016/0165-0327(84)90011-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

1.  Drug screening to identify suppressors of GFAP expression.

Authors:  Woosung Cho; Michael Brenner; Noel Peters; Albee Messing
Journal:  Hum Mol Genet       Date:  2010-06-10       Impact factor: 6.150

2.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of clomipramine.

Authors:  A E Balant-Gorgia; M Gex-Fabry; L P Balant
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

4.  NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo.

Authors:  Akihiro Takano; Sangram Nag; Balázs Gulyás; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

5.  High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer.

Authors:  A E Balant-Gorgia; L Balant; T Zysset
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.